

**Additional file 1: Review of polygenic risk score reports formatting and content**

Study/Provider	Condition(s) reported/selected	Presentation of risk (inc. absolute vs relative, percentile vs risk groups)	Visual aids (presence, format, colour)	Information included	Reference
Fenton et al.	<ul style="list-style-type: none"> <li>▪ Melanoma</li> </ul>	<ul style="list-style-type: none"> <li>▪ Absolute risk (remaining lifetime)</li> <li>▪ Relative risk (compared to others same age &amp; sex)</li> <li>▪ Risk group (low, average, high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Icon array (100 person)</li> </ul>		1
Forrest et al.	<ul style="list-style-type: none"> <li>▪ Breast cancer</li> </ul>	<ul style="list-style-type: none"> <li>▪ Relative risk</li> <li>▪ Absolute risk (lifetime)</li> <li>▪ Risk group (ex: high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Compared 2 visual tools</li> <li>▪ Bell curve showing patient (red) &amp; population risk (green), lifestyle risk factors (alcohol &amp; obesity) &amp; BRCA risk</li> <li>▪ Icon array of 100 women (pink, full symbols for patient's risk)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Methods and genomic variants tested</li> </ul>	2
Brockman et al.	<ul style="list-style-type: none"> <li>▪ Coronary artery disease</li> </ul>	<ul style="list-style-type: none"> <li>▪ Relative risk (inc. percentile)</li> <li>▪ Risk group (reduced, average, increased)</li> <li>▪ Population risk</li> </ul>	<ul style="list-style-type: none"> <li>▪ Bell curve showing patient's risk in green (low), grey (average) or red (high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Information about condition, family testing, recommendations, PRS calculation, insurance implications</li> </ul>	3
P5 Study	<ul style="list-style-type: none"> <li>▪ Type 2 diabetes, coronary heart disease, venous thrombosis</li> </ul>	<ul style="list-style-type: none"> <li>▪ Absolute risk (10y)</li> <li>▪ Risk group (low, increased, high, very high)</li> <li>▪ Risk calculator (inc. lifestyle risk factors)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Thermometer &amp; bell curve with person diagram (green/yellow/pink)</li> <li>▪ Bar graph showing patient vs population risk at current age &amp; patient's risk in 10y</li> </ul>	<ul style="list-style-type: none"> <li>▪ Information about condition, lifestyle recommendations, test methodology</li> </ul>	4
CanRisk	<ul style="list-style-type: none"> <li>▪ Breast &amp; ovarian cancer</li> </ul>	<ul style="list-style-type: none"> <li>▪ Absolute risk (5y, 10y &amp; remaining lifetime)</li> <li>▪ Risk group (near population, moderate, high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Icon array</li> <li>▪ Line graph showing patient vs population risk (blue/grey)</li> </ul>		5
GeneRISK Study	<ul style="list-style-type: none"> <li>▪ Atherosclerotic cardiovascular disease</li> </ul>	<ul style="list-style-type: none"> <li>▪ Absolute risk (10y, lifetime)</li> <li>▪ Risk group (low, moderate, high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Scale bar showing patient's risk (orange)</li> <li>▪ Line graph showing patient's risk (orange) compared to average population (blue)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Modifiable risk factors</li> </ul>	6
eMERGE study	<ul style="list-style-type: none"> <li>▪ Breast cancer</li> <li>▪ Type 2 diabetes (selected)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Relative risk</li> <li>▪ Absolute risk (lifetime)</li> <li>▪ Risk group (high, not high)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Icon array</li> <li>▪ Bell curve showing patient's risk (red)</li> </ul>	<ul style="list-style-type: none"> <li>▪ Information about condition, recommendations, test methodology &amp; limitations</li> </ul>	7

23andMe	<ul style="list-style-type: none"> <li>Coronary artery disease (selected)</li> </ul>	<ul style="list-style-type: none"> <li>Absolute risk (by certain age)</li> <li>Risk group (ex: increased)</li> </ul>	<ul style="list-style-type: none"> <li>Scale bar (green/yellow/red)</li> </ul>	<ul style="list-style-type: none"> <li>Information about condition, lifestyle recommendations, test methodology &amp; limitations (ancestry)</li> </ul>	<sup>8</sup>
MyGeneRank	<ul style="list-style-type: none"> <li>Coronary artery disease (example)</li> </ul>	<ul style="list-style-type: none"> <li>Absolute risk</li> <li>Risk group (ex: moderate)</li> </ul>	<ul style="list-style-type: none"> <li>Scale bar (blue/red)</li> </ul>	<ul style="list-style-type: none"> <li>Recommendations</li> </ul>	<sup>9</sup>
Myriad Genetics	<ul style="list-style-type: none"> <li>Breast cancer (example)</li> </ul>	<ul style="list-style-type: none"> <li>Absolute risk (remaining lifetime, compared to population)</li> </ul>	<ul style="list-style-type: none"> <li>Bar graph showing patient vs population risk (pink/grey)</li> </ul>	<ul style="list-style-type: none"> <li>Test methodology, recommendations</li> </ul>	<sup>10</sup>
Ambry Genetics	<ul style="list-style-type: none"> <li>Breast cancer</li> <li>Prostate cancer</li> </ul>	<ul style="list-style-type: none"> <li>Relative risk</li> <li>Absolute risk (lifetime, compared to population)</li> </ul>	<ul style="list-style-type: none"> <li>Bar graph comparing patient (pink/blue) to baseline (grey)</li> </ul>	<ul style="list-style-type: none"> <li>Test methodology, recommendations left to the discretion of healthcare provider</li> </ul>	no longer available

### References:

- Fenton GL, Smit AK, Freeman L, Badcock C, Dunlop K, Butow PN, et al. Development and evaluation of a telephone communication protocol for the delivery of personalized melanoma genomic risk to the general population. *J Genet Couns*. 2018;**27**:370-80.
- Forrest LE, Sawyer SD, Hallowell N, James PA, Young MA. High-risk women's risk perception after receiving personalized polygenic breast cancer risk information. *J Community Genet*. 2019;**10**:197-206.
- Brockman DG, Petronio L, Dron JS, Kwon BC, Vosburg T, Nip L, et al. Design and user experience testing of a polygenic score report: a qualitative study of prospective users. *BMC Med Genomics*. 2021;**14**:238.
- Marjonen H, Marttila M, Paaajanen T, Vornanen M, Brunfeldt M, Joensuu A, et al. A Web Portal for Communicating Polygenic Risk Score Results for Health Care Use-The P5 Study. *Front Genet*. 2021;**12**:763159.
- Carver T, Hartley S, Lee A, Cunningham AP, Archer S, Babb de Villiers C, et al. CanRisk Tool-a web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants. *Cancer Epidemiol Biomarkers Prev*. 2021;**30**:469-73.
- Widén E, Junna N, Ruotsalainen S, Surakka I, Mars N, Ripatti P, et al. How communicating polygenic and clinical risk for atherosclerotic cardiovascular disease impacts health behavior: an observational follow-up study. *Circ Genom Precis Med*. 2022;**15**:e003459.
- Linder JE, Allworth A, Bland HT, Caraballo PJ, Chisholm RL, Clayton EW, et al. Returning integrated genomic risk and clinical recommendations: The eMERGE study. *Genet Med*. 2023;**25**:100006.
- 23andMe. Coronary artery disease report. [https://medical.23andme.com/wp-content/uploads/2020/06/cad\\_increased.pdf](https://medical.23andme.com/wp-content/uploads/2020/06/cad_increased.pdf). Accessed July 2024.
- MyGeneRank. Coronary artery disease report. <https://mygenerank.scripps.edu/>. Accessed July 2024.
- Genetics M. Personalized cancer risk management report. <https://myriad.com/genetic-tests/myrisk-hereditary-cancer-risk-test/>. Accessed July 2024.